[1] 王琳, 杨雪, 肖玲芳, 等. 蒽环类药物心脏毒性分析及临床使用建议[J].中国现代医学杂志, 2017, 27(12):101-105.
[2] 马军, 沈志祥, 秦叔逵. 防治蒽环类抗肿瘤药物心脏毒性的中国专家共识(2011 版) [J].临床肿瘤学杂志, 2011, 16(12):1122-1129.
[3] 张楚婕, 程蕾蕾, 宋飞艳, 等. Tei指数联合血清超敏肌钙蛋白T早期诊断蒽环类化疗药物致心脏毒性的价值 [J].中华超声影像学杂志, 2017, 26(5):387-392.
[4] Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients [J].Br J Cancer,2011, 105(11):1663-1688.
[5] Neilan TG, Blake SL, Ichinose F,et al. Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin [J].Circulation,2007, 116(5):506-514.
[6] Hayek ER, Speakman E, Rehmus E. Acute doxorubicin cardiotoxicity [J].N Engl J Med,2005, 352(23): 2456-2457.
[7] 杨凯, 张筱骅. 血清cTnI和BNP联合检测对含蒽环类药物化疗药物心脏毒性的预测价值 [J].山东医药, 2014, 54(26): 45-46.
[8] 徐欣怡, 黄美蓉. 蒽环类抗肿瘤药物的心脏毒性 [J].临床儿科杂志, 2010, 28(7): 694-696, 700. |
2019, Vol. 36 
